Onxeo: Disclosure of total number of voting rights and number of shares in the capital at June 30, 2015

Regulatory News:

Onxeo (Paris:ONXEO) (NASDAQ OMX:ONXEO):

Pursuant to article L.233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority):

About Onxeo

Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives to "make the difference”. The Onxeo teams are determined to develop innovative medicines to provide patients with hope and significantly improve their lives.

Key products at advanced development stage are:
Livatag^® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma
Validive^® (Clonidine Lauriad^®): Positive complete results of the Phase II trial in severe oral mucositis
Beleodaq® (belinostat): registered in the US in 2^nd line treatment of peripheral T-cell lymphoma

For more information, visit the website www.onxeo.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20150707005151/en/